Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I am willing to listen to any public Pfizer acknowledgment you can show me that says Bill Gates is involved with Pfizer and BioNTech late-stage trial data which shows Covid vaccine is more than 90% effective in preventing infection.
In the meantime IPIX has not even got a Covid-19 Phase 2 trial started as of today.
Stock being dumped.
THIS IS HUGE NEWS!! Market rallying
Pfizer, BioNTech say late-stage trial data shows Covid vaccine is more than 90% effective in preventing infection
IPIX will be in a phase 2 trial when?
90% effective vaccine.
Pfizer, BioNTech say late-stage trial data shows Covid vaccine is more than 90% effective in preventing infection
How does this impact IPIX?
Brilacidin COVID-19 Preprint Now on BioRxiv.org
Dear Shareholders,
We are pleased to inform shareholders that the Brilacidin preprint article based on in vitro anti-SARS-CoV-2 research conducted at George Mason University’s National Center for Biodefense and Infectious Diseases can now be viewed in its entirety on BioRxiv.org at the link below. The paper strongly supports Brilacidin’s COVID-19 treatment potential.
https://www.biorxiv.org/content/10.1101/2020.10.29.352450v1.full
How many days till 2021? Ipix 2020
Volume 1,228,966 shares
$ 0.217 -.001 - .4587 %
Very helpful information on IPIX.
The number doesn’t even seem current. Hard to know and throw that into the mix and take your pick. Let’s hope the 10-Q will give a more current Overall Share Count reflection.
Going red, fill the gap.
Outstanding Shares 349,579,992
Authorized Shares 600,000,000
9/30/2020
Outstanding Shares 349,579,992
Authorized Shares 600,000,000
9/30/2020
When will the dilution slow down?
November 16th 10-Q is due.
Trial starting, or is it Happy Thanksgiving and then Happy New Year?
2021 trial start would be a disappointment.
$0.214 up 6.4958% Volume today 3,043,127
Volume 2,994,101 today, currently.
Who is selling?
The gap has not been filled yet.
Today’s PR feels as spooky as Halloween.
Dr Menon’s employment was terminated.
Dr Menon where are you !!!!??
Feels like a dark winter at IPIX.
“Leo has agreed to do my podcast under the condition that it is never aired publicly.”
Would love to even just read an interview of challenging questions.
10-Q due November 16th. What will it say?
When does Brilacidin’s patent expire?
No news, 10-Q is not far away.
No Press Release, damn. What’s up??
.12 cents
Aspire is back ?
Yes, a shareholder update, Happy Halloween, and Happy Thanksgiving Press Release is in order.
Wild goose chases never work.
Alfasigma....... eom.
Still no news? Shareholders are beginning to ask questions. Uh oh.
Yep, that’s it. You have to read it to believe it.
Icing on the cake is, in the end we never even got to see the data. It was never released.
Anyone remember the Prurisol early read out that never happened? Then Leo told a poster it wouldn’t happen before saying it publicly?
I bet LR remembers.
Diffusion Pharmaceuticals Appoints Dr. Chris Galloway as Chief Medical Officer
Source: GlobeNewswire Inc.
Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced the appointment of Christopher D. Galloway, M.D. to Chief Medical Officer, effective immediately. Dr. Galloway will report to Robert Cobuzzi, Ph.D., Diffusion’s Chief Executive Officer.
Dr. Galloway is board certified in Emergency Medicine and will assume responsibility of leading the Company’s product development efforts, including clinical trials with Trans Sodium Crocetinate (“TSC”), which is being evaluated in an ongoing Phase 1b clinical study in Romania in patients with COVID-19. In addition, Dr. Galloway will lead the expansion of the Company’s work with TSC into other hypoxia-related conditions. Dr. Galloway brings to Diffusion more than 20 years of experience both in industry leadership roles in clinical development and medical affairs across multiple therapeutic areas and stages of development, as well as the perspective of a practicing physician.
“We are delighted to welcome Chris as a member of the Diffusion team. He brings a breadth of therapeutic area experiences both as a practicing physician and from his time in the biopharmaceutical industry. His leadership will be of significant benefit for Diffusion as we continue and expand the development of TSC for conditions and diseases where low oxygen levels are an issue, including respiratory diseases, such as COVID-19, oncology, and other hypoxia-related conditions,” said Dr. Cobuzzi.
Dr. Galloway joins Diffusion from La Jolla Pharmaceuticals, where he has served as Senior Medical Director in critical care since August 2018. Among his duties at La Jolla, he chaired and oversaw the investigator-initiated and collaborative research programs, as well as supported the commercial and medical teams for the launch of GIAPREZA™ (angiotensin II). Prior to La Jolla, he was Medical Director for global clinical development at the immuno-oncology company, Rakuten Medical. At Rakuten, he was involved in clinical development, operations, and trial execution from Phase 1 through Phase 3 in multiple indications. Previously he has served as Medical Affairs Director within Merck’s immunotherapy division, and also led the team at DaVita Clinical Research as Medical Director and Principal Investigator specializing in early phase studies.
“I am thrilled to be joining the talented team at Diffusion and overseeing the development of our lead product, TSC,” said Dr. Galloway. “Hypoxia-related pathology is prevalent across a multitude of medical conditions and therapeutic disciplines, and I believe TSC has the potential for meaningful improvement in patient care and outcomes.”
Dr. Galloway received his M.D. degree from the University of Texas Medical Branch at Galveston, and completed his residency in Emergency Medicine at Carolinas Medical Center in Charlotte, N.C. He received a BA in biology from the University of Texas at Austin, and is licensed to practice medicine in Colorado. Dr. Galloway is a Diplomate of the American Board of Emergency Medicine.
Inducement Grant Under NASDAQ Listing Rule 5635(c)(4
In connection with Dr. Galloway’s new employment, the Compensation Committee of Diffusion’s Board of Directors has approved the grant of non-qualified stock options to Dr. Galloway, who will receive options to purchase 200,000 shares of Diffusion’s common stock. The grant date for the options will be October 19, 2020, and the exercise price per share for such stock options will be the closing price of Diffusion’s common stock on such date, as reported by NASDAQ. The grant was approved and will be made as an inducement material to Dr. Galloway’s acceptance of employment with Diffusion, in accordance with NASDAQ Listing Rule 5635(c)(4).
The options will have a 10-year term and will vest on a monthly basis over the 36 months after the date of grant, subject to Dr. Galloway’s continuous employment with Diffusion through each applicable vesting date. In addition, the options will be subject to acceleration or forfeiture upon the occurrence of certain events as set forth in Dr. Galloway’s option and employment agreements.
More transparency is needed. Will Leo give an update...an interview...clarify things? I can’t stand these quiet periods.
“President Trump owes his life to Leo and the amazing Brilacidin. I’d expect President Trump to confirm this tonight. Unless Leo requested that he keep it quiet to catch the shorts with their pants down.”
Maybe it’s a November 2 announcement or 60 Minutes will break the story.
How far is Mar a Lago from Boca Raton ??
Another awakening. Wow. I will be watching the IPIX trading Monday morning.
I wish we had a current share count